Forgot Password?
Return to Course Listing

CME: Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies

Activity Description / Statement of Need:

In this online self-learning program:

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly. The pathophysiology of CIDP is not completely understood but involves several humoral and cell-mediated mechanisms. Symptoms of CIDP include progressive limb weakness, usually with a predilection for proximal muscles, and sensory loss and are monophasic and progress for 8 weeks or more.

Target Audience:

Healthcare professionals specializing in: neurology, internal medicine; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in neurology; and those who otherwise commonly care for or clinically encounter patients with CIDP.


This program is supported by an educational grant from CSL Behring.

This activity is free of charge.


Release Date: July 15, 2020 -- Expiration Date: July 15, 2022

Faculty: Tahseen Mozaffar, MD

Agenda

Faculty introduction, disclosures

Introduction content

  • Pathophysiology and presentation of CIDP
  • Incidence and prevalence
  • Misdiagnosis and differential diagnoses

Diagnosis and treatment of CIDP

  • Currently available clinical guidelines (EFNS/PNS)
  • Diagnosis of CIDP: Electrodiagnostic criteria
  • Diagnostic support: Lab evaluation, nerve imaging
  • Currently available treatment options (immunoglobulin, corticosteroids, plasma exchange)
  • Long-term maintenance of CIDP with immunoglobulin therapy
  • Recent research into subcutaneous immunoglobulin

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the common clinical characteristics of CIDP.
  • Identify components of electrodiagnostic criteria used to diagnose CIDP.
  • Evaluate the present treatment options currently available for the management of CIDP.
  • Identify new and emerging therapies for the treatment of CIDP.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PhysiciansFor maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in this section, then it does NOT provide MOC credit. This activity provides MOC credit only for ABIM.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.  Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-20-028-H01-P. CPE credit effective 7/15/20 and expires 7/15/22.

This is a Application (A)-type activity.

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosures: Tahseen Mozaffar, MD, Professor of Neurology and Pathology & Lab Medicine, Interim Chair, Department of Neurology, University of California, Irvine, has received advisory board and/or research funding from Abbvie, Alexion, Amicus, Argenx, Audentes, Sanofi-Genzyme, Sarepta, Spark Therapeutics, Myositis Association, the Muscular Dystrophy Association, the National Institutes for Health, Bristol-Myers-Squib, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, UCB, and Valerion.

Disclosures of Educational Planners: Charles Turck, Pharm, DBCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from CSL Behring.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care

Transthyretin amyloidosis (ATTR) and its complications: optimizing management strategies

Parkinson's disease: optimizing pharmacotherapeutic management strategies and addressing clinical challenges

Migraine Headaches: Therapeutic Updates and Contemporary Management Strategies